AEENA Dx is a technology company.
AEENA Dx has raised $48K across 1 funding round.
AEENA Dx has raised $48K in total across 1 funding round.
AEENA Dx was a Silicon Valley-based diagnostics company specializing in innovative salivary testing platforms, particularly for non-invasive cancer detection such as breast cancer proof-of-concept, alongside offerings in genomics, Pap tests, and pathology.[2][4] It served healthcare providers and patients by addressing needs in point-of-care (POC), over-the-counter (OTC), and at-home diagnostics, solving problems like accessible, scalable testing for infectious diseases, women's health, cardiac markers, drugs of abuse, and cancer through its salivary collection device and diagnostic technology.[1][4] The company merged with NOWDx in a pivotal deal, forming NOWDiagnostics (NOWDx), which combines AEENA Dx's salivary cancer platform with NOWDx's blood/saliva collection and quantitative reader tech, positioning the entity to target the $100 billion global diagnostics market with production capacity exceeding 2 million tests monthly.[1]
Post-merger, growth momentum centers on commercializing launched tests (e.g., for syphilis and strep) and advancing a robust R&D pipeline, led by AEENA Dx's leadership integrating into NOWDx's operations in Springdale, Arkansas.[1]
AEENA Dx emerged as a Silicon Valley startup focused on groundbreaking diagnostics, co-founded by CTO Shivani Nautiyal and CSO Kevin Clark, with CEO Rob Weigle at the helm pre-merger.[1][4] The idea stemmed from developing a "game-changing" salivary cancer diagnostic platform and collection device, starting with proof-of-concept for breast cancer detection and expanding to other critical areas like women's health and infectious diseases.[1][2] Early traction included establishing this non-invasive tech foundation, attracting board members like Michele Colucci and investors tracked in specialized databases, humanizing its mission to democratize healthcare access.[1][5] A pivotal moment arrived with the merger announcement with NOWDx, blending AEENA Dx's innovation with manufacturing scale to accelerate global impact.[1]
AEENA Dx rode the wave of non-invasive, POC diagnostics trends, capitalizing on post-pandemic demand for at-home and rapid testing amid a $100 billion market fueled by aging populations, chronic disease prevalence, and healthcare accessibility gaps.[1] Timing was ideal as salivary tech addressed limitations in invasive sampling, aligning with shifts toward scalable, quantitative readers for infectious, oncologic, and women's health needs.[1][2][4] Market forces like manufacturing scale (2M+ tests/month via merger) and R&D pipelines favor it against rivals, influencing the ecosystem by pioneering saliva-based cancer detection and enabling global patient reach through combined offerings.[1]
NOWDx, powered by AEENA Dx's tech, is primed to lead in high-impact diagnostics with syphilis/strep launches and oncology expansions, potentially dominating POC/OTC segments via its Arkansas hub and C-suite synergies.[1] Trends like AI-enhanced assays and regulatory tailwinds for non-invasive tests will shape its path, evolving its influence from startup innovator to global healthcare disruptor serving millions.[1][2] This merger trajectory echoes AEENA Dx's core promise: transforming diagnostics from lab-bound to everyday accessible tools.
AEENA Dx has raised $48K in total across 1 funding round.
AEENA Dx's investors include Ambit Health Ventures, Esplanade HealthTech Ventures, Good Growth Capital.
AEENA Dx has raised $48K across 1 funding round. Most recently, it raised $48K Series A in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $48K Series A | Ambit Health Ventures, Esplanade HealthTech Ventures, Good Growth Capital |